We found that in both AML samples that resulted from lineage-switching events the expression of KMT2C is downregulated, however, this difference was only significant in the 152985 sample that lineage switched during treatment with the menin inhibitor (Fig. 8a). The gene discussed is KMT2C; the disease is acute myeloid leukemia.